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One effect of stressors such as chronic drug administration is that sequence within the terminal exon of the transcription factor
FosB is recognized as intronic and removed by alternative splicing. This results in an open-reading-frame shift that produces
a translation stop codon and ultimately a truncated protein, termed DFosB. In vitro splicing assays with control and mutated
transcripts generated from a fosB mini-gene construct indicated a CU-rich sequence at the 39 end of intron 4 (I4) plays an
important role in regulating fosB pre-mRNA splicing due to its binding of polypyrimidine tract binding protein (PTB). PTB
binding to this sequence is dependent upon phosphorylation by protein kinase A and is blocked if the CU-rich sequence is
mutated to a U-rich region. When this mutated fosB minigene is expressed in HeLa cells, the splicing efficiency of its product is
increased compared to wild type. Moreover, transient transfection of PTB-1 in HeLa cells decreased the splicing efficiency of
a wild type fosB minigene transcript. Depletion of PTB from nuclear extracts facilitated U2AF
65 binding to wild type sequence
in vitro, suggesting these proteins function in a dynamic equilibrium to modulate fosB pre-mRNA alternative splicing. These
results demonstrate for the first time that phosphorylated PTB promotes intron retention and thereby silences the splicing of
fosB I4.
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INTRODUCTION
Fos and jun are immediate early genes that are expressed rapidly
and transiently in the nucleus accumbens (NAc) and other regions
of the brain in response to a variety of stressors such as substantia
nigra lesions, drug withdrawal and electrical stimulation [1,2,3,4].
These genes encode proteins that are members of the activator
protein 1 (AP-1) family of transcription factors. The transcription
factors form either heterodimers or homodimers and activate
expression by binding to AP-1 sites upstream of particular genes,
such as those encoding growth factors and neurotransmitters [1].
Products of the fos gene family include cFos, Fos-related antigens
(referred to as Fra1 and Fra2) and FosB.
While the 45 kDa FosB protein is only transiently expressed in
the brain, DFosB, a 33–37 kDa splice variant of FosB, accumulates
in a region-specific manner as a common response to chronic
stimuli [4,5,6,7,8]. DfosB mRNA is produced by removal of intron
4 (I4) within the terminal exon of the fosB pre-mRNA. This
regulated splicing event results in translation termination and the
production of a truncated protein. Three factors have been
identified that contribute to DFosB protein accumulation. These
include the repeated activation of the fosB gene and induction of
DfosB mRNA [9]; the absence of a C-terminal destabilizing
domain in the case of DFosB protein, but not for the other
members of the Fos family [10]; and the phosphorylation of an N-
terminal serine residue on DFosB, which is important in inhibiting
proteosomal degradation [11].
Sequencing of the human genome resulted in the surprising
finding that more than 42% of the genes produce pre-mRNAs that
are alternatively spliced [12,13,14,15]. Many of the regulated
splicing events occur in neurons and the molecular basis of the
neural specificity is only beginning to be understood [16,17].
Coding sequences of eukaryotic genes (exons) are interspersed by
non-coding sequences (introns) that can be removed from the pre-
mRNA by splicing in either a constitutive or a regulated manner.
The accurate elimination of these non-coding regions requires
a conserved 59 splice site, a branch point sequence, and
a polypyrimidine tract that precedes the 39 splice site. In-
terestingly, recent research has indicated that elements critical
for the regulation of pre-mRNA splicing may also be found both
proximal and distal to the traditional splice sites. These sequences
are termed enhancer or silencer elements and can be functional
within both introns or exons [18]. Whether the sequence acts as an
activator or inhibitor of splicing appears to be context-dependent
[19]. Two well-studied examples of exon skipping are those of c-src
and GABAA receptor c2 subunit pre-mRNAs, which contain the
pyrimidine-rich sequences CUCUCU, UUCUCU, UUCCUU
and CUUCUUC [20,21,22]. PTB binds these sequences and by
doing so functions to silence splicing. The sequence CUCCU-
CUUCC within transcript generated from the human calcitonin/
calcitonin gene-related peptide (CT/CGRP) gene also binds PTB
but in this case it enhances inclusion of the adjacent exon 4 into
the mRNA [23]. A CU-rich sequence similar to these examples is
found proximal to the 39 end of fosB I4. More recently it was
reported that PTB can also counteract the splicing inhibitory
activity of SRp30c [24].
Along with identifying target genes that are regulated by the Fos
family of transcription factors, recent work has focused on
deciphering the regulation of FosB isoform expression. In this
study we have used an in vitro splicing system to identify PTB as
a factor that binds the 39 end of fosB I4 in a PKA phosphorylation-
dependent manner. A CU-rich sequence is required for PTB
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e828binding and regulates I4 retention in vitro as well as in vivo. We also
show that U2AF
65, a factor important in the assembly of the
splicing machinery, can bind to the 39 end of fosB I4. Interestingly,
reducing the amount of PTB bound to the 39 end of fosB I4, by
either PTB depletion or mutation of the CU-rich PTB binding
element, results in increased binding of U2AF
65 to fosB I4. These
findings support a model in which a competition between PTB
and U2AF
65 regulates fosB I4 retention.
RESULTS
The two splice variants of fosB are products of intron retention
(fosB) and intron excision (DfosB). A sequence of 140 nt proximal
to the 39 end of the fosB pre-mRNA (Fig. 1A) is removed by
splicing to produce DfosB mRNA. Visual inspection of the 59 and
39 splice sites of the regulated fosB intron, I4, and the upstream
and downstream exons 4 and 5 (E4 and E5), revealed that it has
been very well conserved between humans, rats and mice (Fig. 1B).
However, comparison of the I4 splice site of mammals with that of
fish indicated that regulated fosB pre-mRNA splicing has not been
evolutionarily conserved among all vertebrates (Fig. 1B). The 39
splice site of the mammalian fosB I4 is suboptimal when compared
to the splice site consensus sequence. One notable change from the
consensus sequence is that the first nucleotide of the downstream
exon is a U, which deviates from the G present in the consensus
sequence. This deviation produces a sequence similar to the
consensus 59 splice site sequence, thereby potentially creating
a pseudo 59 splice site adjacent to the 39 splice site (Fig. 1B,
underlined sequence). The weakness of this splice site is likely to be
an important factor in why I4 is usually retained when fosB is
expressed.
Characterization of I4 Binding Proteins
With regards to splicing regulation, the binding of cis-acting RNA
elements becomes very important in dictating whether the
spliceosome is recruited to weak splice sites within the pre-mRNA.
In order to identify factors that are necessary for the regulated
splicing of I4, we created a fosB minigene containing exon 4, intron
4 and exon 5 (E4, I4 and E5). The fosB sequence was cloned
downstream to a T7 polymerase promoter to facilitate production
of transcripts. Previous studies showed that serum stimulated
HeLa cells produce both FosB and DFosB and, therefore, the
factors essential for the recognition of I4 are present in these cells
[25]. In order to determine which proteins bound to I4 of fosB,
radioactively-labeled transcripts were prepared from the 59,
middle and 39 end of the intron (refer to Fig 1A) and used as
substrates in UV cross-linking assays (Fig. 2A). The results from
these studies indicated that different subsets of proteins bound to
each portion of the intron and that an abundant 59 kDa protein
bound the 39 end of the intron (Fig. 2A, lanes 1–6). Visual
inspection of the sequence at the 39 end of the intron indicated
that a putative PTB binding site is present within the
polypyrimidine tract at the end of the sequence (Fig. 1A,
underlined sequence). PTB is approximately 59 kDa and it binds
CUCUCUU sequences in other regulated transcripts [20,21,22].
A cross-linking immunoprecipitation assay using an antibody
specific for PTB or a control antibody showed that PTB bound to
the 39 end of fosB I4 (Fig. 2B, lane 3).
PTB Regulates Retention of FosB I4
To characterize the role of PTB in the regulation of FosB pre-
mRNA splicing, HeLa cells were co-transiently transfected with
Figure 1. Comparison of fosB I4 sequence among vertebrates. (A) The filled boxes at the top represent fosB exons. The horizontal lines between the
boxes represent the three constitutively spliced introns that are removed from the pre-mRNA generated from the gene encoding FosB. The regulated
fourth intron is located between the bold-faced vertical lines. Shown below the pre-mRNA is the I4 sequence from the mouse fos b gene. The
sequence to the left of the first//represents the 59 I4 transcript; the sequence between the two sets of//represents the middle I4 transcript; the
sequence to the right of the second//represents the 39 I4 transcript. The sequence that is underlined is the PTB binding site. (B) Diagrammatic
representation of the consensus splice sites, branch point and pyrimidine tract sequences for vertebrates. The human, rat, mouse and fish fosB I4
splice sites are indicated below. Capital letters represent exonic sequence and lowercase letters represent intronic sequence, n denotes any
nucleotide, y for pyrimidines, r for purines and p(y)tract for the polypyrimidine tract, the underlined sequence shows the putative decoy 59 splice site.
doi:10.1371/journal.pone.0000828.g001
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(bluescript, pBS) or a construct containing cDNA corresponding to
PTB 1. Forty-eight hours post-transfection RNA was isolated from
the transfected cells and cDNA prepared. Ectopically expressed
fosB sequence was amplified by semi-quantitative PCR using
primers complementary to sequence within the vector and exon 5
(Fig 3). Expression of PTB 1 by transient transfection resulted in
a significant decrease in fosB I4 splicing. This effect was gradually
diminished when decreasing amounts of the PTB 1 plasmid were
used in the transfection assay.
Analysis of the PTB Binding Site Within the 39 End of
I4
We next sought to repress the expression of PTB within HeLa cells
by siRNA technology and determine what effect this would have
on the level of splicing of transcripts generated from the fosB
minigene construct. Although we were able to reduce both the
mRNA and protein levels of PTB (data not shown), we were not
able to achieve enough of a reduction to have a significant effect
on the splicing of transcripts generated from the fosB minigene
construct. Therefore, we undertook an alternative approach. The
fosB minigene was modified by site-directed mutagenesis in such
a manner that the PTB binding site within the 39 end of I4 was
eliminated, but the pyrimidine-rich nature of the sequence was
maintained (Fig. 4A, ISS/T6). This construct was then used for
both in vitro splicing assays and transient transfection in HeLa cells
to further explore the functional effects of the mutation. This
approach eliminates the non-target artifacts obtained by siRNA
technology. In addition, the global decrease of PTB within cells
induced by siRNAs would effect numerous other pre-mRNA
reactions and biological processes that are regulated by PTB
besides fosB splicing. By contrast, the dominant negative mutation
exclusively disrupts the interaction of PTB with fosB I4. Thus,
using this approach we are able to obtain a more focused analysis
of the role of PTB in the regulated splicing of fosB pre-mRNA.
Transcripts corresponding to the 39 end of fosB I4 were
generated from wild type and mutant constructs and used in cross-
linking immunoprecipitation assays. The mutations within the
CU-rich region disrupted PTB cross-linking to the 39 sequence of
fosB I4 (Fig. 4A, compare lanes 1–4 to lanes 5–8). The results from
these studies indicated that one element critical for PTB binding
was within the CUCUU sequence.
In order to assess whether PTB regulates processing of the fosB
pre-mRNA, in vitro splicing assays were performed with transcripts
prepared from constructs containing the ISS/wild type sequence
or the ISS/T6 mutation (Fig. 4B). The sizes of the intron retained
(IR), intron spliced (IS) and E4 RNAs are 444, 303 and 207
nucleotides (nt), respectively. The products of the splicing assays
were confirmed by eluting RNA from the gel and amplifying by
PCR using intron- and exon-specific primers (Table 1). Amplifi-
Figure 2. PTB binds to the 39 end of fosB I4. (A)
32P-labeled mini RNA
substrates from the 59, M and 39 region of I4 were incubated in the
absence (2) or presence (+) of HeLa nuclear extract before UV cross-
linking, resolved by gel electrophoresis and visualized by autoradiog-
raphy. (B)
32P-labeled mini RNA substrates from the 59, M and 39 region
of I4 were incubated in the presence of HeLa nuclear extract before UV
cross-linking. The samples were then immunoprecipitated with
antibody that recognizes PTB or a control antibody that does not
recognize splicing factors, resolved by gel electrophoresis and
visualized by autoradiography. The 59,Ma n d3 9 substrates are
transcripts from three regions of the intron as defined in the legends
of Fig. 1. The position of protein molecular weight markers is indicated
on the right in kDa.
doi:10.1371/journal.pone.0000828.g002
Figure 3. In vivo splicing of fosB I4 is regulated by PTB. (A) HeLa cells
were transiently co-transfected with ISS/WT and either a control
plasmid (bluescript) and/or a construct containing cDNA corresponding
to PTB 1. Addition of the control plasmid ensured equal levels of DNA
within the transfection assay. The amounts of PTB 1 plasmid used per
well in the transfection assays were 1.5 (dark grey box), 1.0 (stripped
box) and 0.5 mg (stippled box). The data is representative of single
experiment in which all conditions were performed in duplicate. The
splicing products of the fosB mini-gene transcripts were analyzed by
semi-quantitative PCR using primers that detect both the intron
retained transcript (IR) and the intron spliced transcript (IS). An example
of the PCR products generated from ISS/WT transcripts isolated from
HeLa cells co-transfected with either bluescript (A) or PTB 1 (B) is shown
in the inset. The data is represented as the ratio of IS to IR mRNA. Bars
display the standard error, *p,0.05.
doi:10.1371/journal.pone.0000828.g003
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181 nt, respectively, while the size of the amplified lariat structure
was 150 nt (Fig. 4C). The results from the splicing assays showed
that when compared to ISS/wild type, the amount of IS increased
and IR decreased when the splicing reaction contained ISS/T6 as
the source of the transcript (Fig. 4B, lanes 2 and 4). These findings
provide support for a regulatory role of PTB in the alternative
splicing of the fos B pre-mRNA.
ISS/WT or ISS/T6 reporter fosB minigenes were transiently
expressed in HeLa cells to further explore the effects on splicing
due to the loss of binding of PTB to the 39 end of I4. Forty-eight
hours post-transfection RNA was isolated from the transfected
cells, cDNA prepared and then analyzed by semi-quantitative
PCR with a single set of primers that detect both I4 retained and
spliced transcripts generated from the control and mutagenized
fosB minigene constructs. The site directed mutagenesis of the
PTB binding site in the 39 end of I4 resulted in a significant
enhancement of splicing of the fosB minigene transcript (Fig 4D).
These results together with those of the PTB binding assays and in
vitro and in vivo splicing assays established a strong correlation
between PTB binding to the 39 end of fosB I4 and intron
retention. The decrease in the ratio of IS to IR when excess PTB is
present within HeLa cells transfected with ISS/T6 suggests that
other PTB binding sites may be able to influence splicing of the
fosB when the ISS of I4 is mutated. Notably, while the presence
of excess PTB for the control condition (ISS/WT) results in an
,3-fold reduction in the ratio of IS to IR (Fig 3), this reduction for
the experimental condition (ISS/T6) is less than 2-fold (Fig 4D).
This strongly supports the important role of PTB binding
to sequence within the 39 end of I4 for regulated splicing of fosB
pre-mRNA.
Requirement of PTB Phosphorylation for I4
Interaction
Earlier research has shown that phosphorylation can modulate the
intracellular transport of PTB, offering a potential means for
regulation of its activity in the nucleus [26]. In order to determine
whether dephosphorylation of PTB is important for regulating its
binding to fosB I4, His-tagged PTB 1 was expressed by transient
transfection and isolated from HeLa cells. The isolated protein
was cross-linked to the 39 wild type transcript before or after
phosphatase treatment. PTB bound the fosB I4 transcript (Fig. 5,
lane 1), and binding was abolished only when phosphatase
treatment preceded the cross-linking step (Fig. 5, compare lanes 2
and 3). Previously PTB was shown to be phosphorylated by PKA
[26]. In our studies, supplementing the reaction with the catalytic
subunit of PKA and ATP, following the phosphatase treatment,
was sufficient to rescue PTB binding to the 39 transcript (Fig. 5B,
lane 4). Cross-linking of PTB to this transcript prevents any further
disruption of the protein-RNA interaction (Fig. 5, lane 5). The
results from these studies suggested that it is not merely the
presence of a PTB binding site within the 39 end of I4 that
influences the splicing of fosB pre-mRNA, but rather that this
functional interaction is tightly regulated by the PKA-dependent
phosphorylation state of PTB.
Depletion of PTB Results in Enhanced Binding of
U2AF
65 to I4
The CU-rich element characterized in this study is located within
the pyrimidine-rich tract upstream of the fosB I4 39 splice site,
a region to which the constitutive splicing factor U2AF
65 binds.
One explanation for how PTB silences I4 splicing is that it
competes with U2AF
65 for binding to the intron. To test this
Figure 4. The CT-rich sequence of fosB I4 is required for PTB binding
and fosB transcript splicing in vitro and in vivo. (A) Wild type (ISS/WT)
and Mutant (ISS/T6) CT-rich region of fosB I4 sequence. Two nucleotides
indicated by asterisks were mutated to disrupt PTB binding (ISS/T6).
32P-
labeled mini RNA transcripts generated from the 39 regions of I4 within
the ISS/WT and ISS/T6 constructs were incubated in the presence of
increasing amounts of HeLa nuclear extract before UV cross-linking.
Samples were then resolved by gel electrophoresis and visualized by
autoradiography. (B) In vitro splicing reactions containing
32P-labeled
ISS/WT and ISS/T6 fosB pre-mRNA substrate were incubated in HeLa
nuclear extract and the resultant products of splicing were resolved by
gel electrophoresis and visualized by autoradiography. The size the of
RNA markers are shown on the right in nt. IR, IS, IVS-E5 and E4 indicate
the intron retained transcript, the intron spliced transcript, the
intermediate lariat and exon 4, respectively. (C) RNA products from
the gels in (B) were cut out and PCR assays with primers specific for
each product were used to amplify the IR, IS and IVS-E5 products. DNA
markers are indicated on the right in nt. (D) HeLa cells were transiently
co-transfected with ISS/WT (white box) or ISS/T6 mutant fos B mini-
gene sequence (dark grey box) and either a control plasmid (bluescript)
or a construct containing cDNA corresponding to PTB 1. Addition of the
control plasmid ensured equal levels of DNA within the transfection
assay. The amounts of PTB 1 plasmid used per well in the transfection
assays were 1.5 mg (light grey stippled box), and 0.5 mg (dark grey
stippled box). The data is representative of single experiment in which
all conditions were performed in duplicate. The splicing products of the
fosB mini-gene transcripts were analyzed by semi-quantitative PCR
using primers that detect both the intron retained transcript (IR) and
the intron spliced transcript (IS). The data is represented as the ratio of
IS to IR mRNA. Bars display the standard error, *p,0.01.
doi:10.1371/journal.pone.0000828.g004
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nuclear extracts would enhance binding of U2AF
65 to the 39 wild
type sequence of I4. PTB was depleted from the nuclear extracts
by incubation with biotin-labeled PTB substrate and streptavidin
precipitation as previously described [22].
32P-labeled RNA
substrate corresponding to the 39 region of I4 were incubated in
the presence of either control HeLa nuclear extract (Fig. 6A,
lanes 1 and 3) or PTB-depleted HeLa nuclear extract (Fig. 6A,
lanes 2 and 4). Following UV cross-linking, the nuclear extracts
were immunoprecipitated with either an a-PTB antibody (Fig. 6A,
lanes 1 and 2) or an a-U2AF
65 antibody (Fig. 6A, lanes 3 and 4).
Samples were resolved by SDS-PAGE and visualized by
autoradiography. U2AF
65 interaction with the 39 end of I4 was
enhanced when the HeLa nuclear extract was first depleted of
PTB (Fig. 6A, lanes 3 and 4). Additionally, we analyzed the
binding of U2AF
65 to transcripts which contain the mutagenized
PTB binding site within the 39 end of I4.
32P-labeled transcripts
corresponding to the 39 end of fosB I4 generated from ISS/WT
(Fig 6B, lanes 1 and 3) and ISS/T6 (Fig 6B, lanes 2 and 4) were
incubated in the presence of HeLa nuclear extract before UV
cross-linking. Samples were then immunoprecipitated with either
an a-PTB antibody (Fig 6B, lanes 1 and 2) or an a-U2AF
65
Table 1. Oligodeoxynucleotides used in subcloning, PCR, UV cross-linking and mutagenesis studies.
..................................................................................................................................................
Name Sequence Experiment
pG3 forward 59–CTGAGCTATTCCAGAAGTAGTGAGG-39 Transfection analysis
pG3 reverse 59-GCAAGAAGGGAGGGCGAGTTCAGCG-39 Transfection analysis
WT forward 59-AGAAACTGATCAGCTTGAAGAGGAAAAG-39 MiniFosB gene
WT reverse 59-GTACGAAGGGCTAACAACGG-39 MiniFosB gene
59 forward 59-GCATGCTAATACGACTCACTATAGGGTGAGAGA TTTGCCAGG-39 UV cross-linking
59 reverse 59-TCTTCCTTAGCGGATGTTG-39 UV cross-linking
Middle forward 59-GCATGCTAATACGACTCACTATAGGGCGGCTTCGGCTGGCTG-39 UV cross-linking
Middle reverse 59-CTGCTCTGGAAGGGCAGG-39 UV cross-linking
39 forward 59-GCATGCTAATACGACTCACTATAGGGCCGAGACGCACCCCCCA-39 UV cross-linking
39 reverse 59-TGTGTGTAAAGAGAGAAGCCGTCAG-39 UV cross-linking
ISS/T6 forward 59-CACCCCCCAACCTGACGGCTTTTTTCTTTACACACAGTGAAGTTC-39 ISS/T6 mutagenesis
ISS/T6 reverse 59-GAACTTCACTGTGTGTAAAGAAAAAAGCCGTCAGGTTGGGGGGTG-39 ISS/T6 mutagenesis
Exon 4 forward 59-AAAAGGCAGAGCTGGAGTCG-39 PCR of splice products
Exon 5 reverse 59-GTACGAAGGGCTAACAACGG-39 PCR of splice products
Intron 4 forward 59GCATGCTAATACGACTCACTATAGGGCGGCTTCGGCTGGCTG-39 PCR of splice products
doi:10.1371/journal.pone.0000828.t001
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Figure 5. Alkaline phosphatase treatment results in the lack of PTB
binding to the 39 end of fosB I4.
32P-labeled mini RNA substrates from
the 39 region of fosB I4 were incubated in the presence of purified his-
tagged PTB 1 protein and UV cross-linked (lane 1, X). Alternatively,
samples were phosphatase treated either after or before the UV cross-
linking step (lanes 2 and 3, XP and PX, respectively) or phosphatase
digested and kinase treated before or after cross-linking (lanes 4 and 5,
PKX and XPK, respectively). Samples were resolved by gel electro-
phoresis and visualized by autoradiography. The position of a protein
molecular weight marker is indicated on the right in kDa.
doi:10.1371/journal.pone.0000828.g005
Figure 6. PTB and U2AF
65 bind to the 39 end of fosB I4. (A)
32P-labeled
mini RNA substrate transcribed from the 39 region of I4 within the ISS/
WT construct were incubated in the presence of either control HeLa
nuclear extract (lanes 1 and 3) or PTB-depleted HeLa nuclear extract
(lanes 2 and 4) before UV cross-linking. The samples were then
immunoprecipitated with either an a-PTB antibody (lanes 1 and 2) or an
a-U2AF
65 antibody (lanes 3 and 4). Samples were resolved by
electrophoresis and visualized by autoradiography. (B)
32P-labeled mini
RNA substrates transcribed from the 39 region of I4 within either the
ISS/WT (lanes 1 and 3) or ISS/T6 constructs (lanes 2 and 4) were
incubated in the presence of HeLa nuclear extract before UV cross-
linking. The samples were then immunoprecipitated with either an a-
PTB antibody (lanes 1 and 2) or an a-U2AF
65 antibody (lanes 3 and 4),
resolved by electrophoresis and visualized by autoradiography.
doi:10.1371/journal.pone.0000828.g006
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visualized by autoradiography. The decreased level of PTB
interaction with the 39 end of I4 due to the T6 mutation resulted
in a corresponding increase of U2AF
65 binding to the mutagenized
transcript (Figure 6B, lane 2 and 4). In summary, it appears that
PTB and U2AF
65 may compete for binding to the 39 end of fosB
I4 thus providing an additional level of regulation for the splicing
of the fosB pre-mRNA.
DISCUSSION
The brain’s ability to adapt in due course to repeated insults can
be characterized by the longevity of the response, even after the
perturbation has halted. Some examples of such adaptations
include learning and memory as well as drug addiction and severe
stress [1,3]. Understanding the molecular basis underlying the
stability of these responses has received much attention from the
scientific community. The multifaceted process of gene expression
is critical to the brain’s adaptive response. Therein, considerable
research has been focused on the function and regulation of
transcription factors including FosB [8,27,28,29].
FosB has been of particular interest since several isoforms,
generated by alternative splicing, are differentially expressed in the
brain. To date, the expression of DFosB is one of the longest-
lasting molecular changes produced by chronic drug administra-
tion observed in the brain. It is therefore thought to mediate some
of the neural and behavioral changes that occur with drug
addiction [1,30]. DFosB protein accumulates in the NAc and
dorsal striatum of animals chronically treated with cocaine [6].
The truncated protein is produced when a usually retained intron,
I4, is deleted from the fosB pre-mRNA by alternative splicing. The
removal of I4 results in a shift in the open reading frame and
produces a translation stop codon [31]. In this study we show for
the first time that the binding of PTB to a CU-rich region within
the 39 end of fosB I4 prevents the splicing of I4 and hence the
downstream production of mRNA encoding DFosB.
PTB Regulates Intron Retention
In many examples of splicing regulation, the role of PTB is to
enhance exon skipping by antagonizing exon definition [22]. Exon
definition is the standard mode of recognition of splice sites in
vertebrates where genes are composed of relatively short exons
interspersed between long introns. In contrast, yeast and other
organisms with short introns the usual mode of splice site
recognition is by intron definition. The role of PTB in fosB
splicing is somewhat unusual in that it is similar to intron definition
since the I4 is only 140 nt long. Our data suggest that when PTB
binds to fosB pre-mRNA, I4 is retained. Mutating the CU-rich
sequence to a U-rich sequence inhibits PTB binding and the
mutated fosB RNA was more efficiently spliced both in vitro and in
vivo. This result is in agreement with several studies in which PTB
was shown to repress splicing [18,22,32,33,34]. Because the
CU-rich sequence overlaps with the predicted binding site of
U2AF
65, a factor that recognizes the polypyrimidine stretch at the
39 end of introns, one possible mechanism of PTB function is
a simple competition for the binding site [22]. Our finding that
depletion of PTB from the HeLa nuclear extract resulted in
binding of U2AF
65 to the wild type sequence supports this
mechanism. However, in conjunction with competition between
splicing factors, other mechanisms may play a role in the
regulation of fosB pre-mRNA splicing by PTB. One such example
could be the regulation of propagative binding of PTB along
a specific segment of the pre-mRNA [22]. Recent work has
suggested that repression of splicing of the SM exon within the
a-actinin pre-mRNA may be due the cooperative binding of PTB
within the 39 end of the upstream intron out-competing the
binding of U2AF
65 to the polypyrimidine tract [35]. Examination
of the sequence of the fos gene using the biocomputational tool
EMBL-EBI Splicing Rainbow (http://www.ebi.ac.uk) revealed the
presence of three putative PTB binding sites within I4 and exon 5.
The alteration of the splice ratios of transcripts containing I4
within HeLa cells co-transfected with ISS/T6 and PTB 1 suggests
that under certain conditions additional PTB binding sites within
the fos B pre-mRNA may play a role in splicing regulation. The
successive binding of PTB may itself be regulatory by interfering
with the binding of other splicing factors, and/or functioning to
create a scaffold on the pre-mRNA through the molecular
interactions between the bound PTB proteins. Interactions
between upstream and downstream bound PTB could result in
a looping of the RNA, thereby shielding specific sequences from
functionally interacting with both splicing enhancing factors and
the spliceosome [22]. Results from the ISS/T6 mutation clearly
indicate the importance of PTB binding to the 39 end of I4 for the
regulated splicing of fos B pre-mRNA. We are currently
examining if interactions between PTB bound at the 39 end of
I4 and additional sites on the fos B pre-mRNA are important for
regulated splicing.
While preceding models of PTB function suggest a mechanism
of splicing repression by obstruction of splice sites or averting
interaction with the spliceosome through looping of the pre-
mRNA [22,33,34], recent data from the Fas and c-src model
systems suggest a more complex mechanism [36,37]. The
proposed mechanism involves specific interference with the
bridging between U1 small nuclear ribonucleoprotein (snRNP)
and U2AF
65 that is responsible for intron and exon definition.
This form of interference cannot be ruled out in the fosB model. A
unique aspect in the fosB model that makes it different from the
one proposed by Sharma and colleagues [37] is that the I4 39
splice site is a weak splice site that contains a pseudo 59 splice site
with a putative U1 binding site at the I4/E5 border. If U1 snRNP
associated factors indeed bind this site it would most likely block
the binding of factors required for the recognition of the 39 splice
site. Further studies are needed to determine if PTB simply
obstructs the fosB splice site or perhaps prevents cross-talk between
components of the spliceosome and whether factors that bind the
59 splice site are also involved in the regulation of splicing.
Adding further complexity to the regulation of alternative
splicing by PTB is its relationship to brain PTB (nPTB). This
splicing factor is a paralog of PTB that is enriched in neurons and
a few other tissues [27,38,39,40]. Although these two highly
homologous proteins can interact with the same cis-elements on
RNAs, nPTB is a significantly weaker silencer of splicing than PTB
[41]. Interestingly, during neuronal differentiation PTB levels are
decreased via the action of a neuron-specific microRNA which
results in a concurrent increase in the level of nPTB [42].
Additionally, siRNA induced knockdown of PTB also induces the
expression of nPTB [27,43]. It is possible that we did not observe
significant alterations in the splicing of fosB transcripts in cells in
which PTB had been knockdown due to this phenomenon
(Marinescu and Potashkin, unpublished). The analysis of the
intricate dynamics between these proteins indicates that exon
populations possess a graded sensitivity to the repressive effects of
the individual PTB paralogs [43]. We have determined that nPTB
can bind to the 39 end of I4 (data not shown). Whether this
binding is relevant to the splicing of fosB pre-RNA within the
brain is currently unknown but is a focus of ongoing analysis.
The other unique aspect of the function of PTB in the splicing
of fosB is that it is an example of intron retention, as opposed to its
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mechanism for producing multiple products from a single gene.
Intron retention, however, is a relatively rare form of regulated
splicing in vertebrates [44,45], though it is more prominent in viral
splicing. Interestingly, a recent study identified 88 examples in
which a retained intron produced a truncated protein in humans
and in 40% of these cases the premature stop codon was present in
the last exon, similar to fosB [44]. In vertebrates, one well-studied
example of intron retention that is similar to fosB is bovine growth
hormone (bGH) [46]. The regulated intron of bGH also has
suboptimal splice sites. The splicing of bGH is regulated by two
constitutive splicing factors; SF2/ASF stimulates removal of the
final bGH intron and hnRNP A1 inhibits its splicing [47]. Our
results showing that PTB, formerly referred to as hnRNP I,
regulates fosB splicing are consistent with the idea that suboptimal
splice sites are sensitive to fluctuations in regulatory splicing
factors. To our knowledge this is the first example of PTB playing
a role in intron retention.
Phosphorylation of PTB is Critical for RNA Binding
The key factor important for recognition of the suboptimal fosB I4
splice sites may simply be the amount and/or type of PTB present
in the nucleus where regulation is occurring. Our novel finding
that only phosphorylated PTB binds to the 39 intron sequence can
be interpreted as evidence that phosphorylation of this splicing
factor is important for regulation. Recently, it has been shown that
PTB shuttles between the nucleus and cytoplasm, and, that this
movement is dependent on the phosphorylation of PTB [26].
Specifically, phosphorylation on Ser16 can sequester PTB in the
cytoplasmic compartment. These studies did not rule out the
possibility of PTB being phosphorylated on additional sites. Ser16
of PTB is not within the RNA binding domains of PTB. This
would suggest that the effects of PTB phosphorylation observed in
our studies may be due to phosphorylation by PKA on additional
sites that are important for RNA/protein interactions. We are
currently performing mutational analysis of the PKA sites within
PTB to determine which site(s) are critical for regulation of fosB
splicing. Additionally, further studies to characterize the distribu-
tion of phosphorylated PTB under conditions in which the splicing
of fosB is regulated are being carried out in order to fully
understand the role PTB in this process.
MATERIALS AND METHODS
Cloning and mutagenesis
A minigene construct containing the last 156 nucleotides (nt) of
exon 4 (E4), I4 and the first 167 nt of exon 5 (E5) of Mus musculus
fosB was created for use as a template for splicing and binding
assays (a gift of Dr. Y. Nakabeppu, Kyushu University, Japan).
The fosB minigene was amplified by PCR and subcloned into both
the pGEM-T Easy plasmid (Promega, Madison, WI), adjacent to
the T7 promoter to create pEZ_ISS/WT, and a modified pGL3
plasmid (Promega), adjacent to a SV40 promoter to create ISS/
WT for transfection studies.
pEZ ISS/WT was used as a template to generate the mutant
pEZ_ ISS/T6. A set of complementary oligonucleotides contain-
ing the desired mutations was synthesized (Table 1) and used as
primers for site-directed mutagenesis using a Quickchange kit
(Stratagene, La Jolla, CA). Nucleotides 128 and 130 within the
alternatively spliced intron were changed from C to T
(C128T129C130RTTT), in order to convert a putative PTB-
binding site into a pyrimidine-rich sequence not recognized by
PTB. The mutated fosB minigene was amplified by PCR using
50 ng of pEZ_ISS/WT construct, 125 ng of sense and anti-sense
primers, 0.2 mM each of dTTP, dATP, dCTP and dGTP and 2.5
U of PfuTurbo DNA polymerase (Stratagene) in a buffer
containing 10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl
(pH 8.8), 2 mM MgSO4, 0.1% Triton X-100 and 0.1 mg/ml
bovine serum albumin (BSA). Eight percent dimethylsulphoxide
(DMSO) was added to the reaction to increase the specific binding
of the primers. The cycling parameters used were as follows:
denature at 95uC for 30 sec, 20–30 cycles at 95uC for 30 sec, 55uC
for 1 min, and 68uC for 8 min. Reactions were cooled to 37uC
and incubated with Dpn I (10 U/ml) for 1 hr in order to digest the
parental template so that only mutated DNA remains. Constructs
were sequenced to confirm that the mutation. The pEZ_ISS/T6
sequence was also subcloned into a modified pGL3 plasmid
(Promega), adjacent to a SV40 promoter to create ISS/T6 for
transfection studies.
Nuclear extract preparation, transcription and in
vitro splicing assays
Soluble extracts were prepared from nuclei isolated from 11 liters
of HeLa cells grown in spinner cultures using a modification of the
Dignam method [48,49]. Templates for splicing substrates were
generated by digestion of pEZ_ISS/WT with Nar I. Labeled RNA
was synthesized from linear plasmid in a 50 ml reaction containing
2 mg of DNA, 0.4 mM each of ATP and GTP, 0.1 mM UTP and
CTP, 2.5 mlo f[
32P]-UTP and [
32P]-CTP (ICN), 0.5 mM
diguanosine triphosphate and 2 mlo f2 0U / ml T7 RNA poly-
merase Plus (Ambion, Austin, TX). Reactions were incubated at
37uC for 1 hr and then digested with DNase I for 15 min at 37uC.
Transcripts were purified on 4% denaturing polyacrylamide gels,
cut from the gel and eluted on a rotating platform in RNA elution
buffer containing 2 M ammonium acetate, 1% SDS and 25 mg/
ml yeast tRNA at 37uC overnight. RNA substrate was then
extracted with phenol:chloroform and ethanol precipitated. In vitro
splicing assays were done as previously described using 11 mlo f
HeLa extract (2.6 mg/ml) in a total reaction of 25 ml [50]. Spliced
products were separated on 4% denaturing polyacrylamide gels.
Templates for intronic transcripts were prepared by PCR using
oligonucleotides listed in Table 1. All forward primers contained
a T7 RNA polymerase promoter. Each PCR reaction (20 ml)
contained 0.88 ng of pEZ_ISS/WT template, 20 pmol of each
primer, 0.25 ml Taq polymerase (5U/ml, Promega), 2 mlo f1 0 6
Taq buffer (Promega) and 1 ml of dNTP mix containing 10 mM
dATP, dCTP, dGTP and dTTP. The parameters were as follows
for 35 cycles: denaturation at 94uC for 15 sec, annealing for 15 sec
at variable temperatures dependent upon the primers (59 intron
template primers: 53.3uC, middle intron template primers:
73.1uC, and 39 intron template primers: 67.9uC), and extension:
72uC for 30 sec. PCR reactions were then extracted with
phenol:chloroform and ethanol precipitated.
Intronic transcripts were prepared using PCR generated
templates. Transcription reactions (50 ml) contained 2 mgo f
template, 2.5 ml of 200 U/ml T7 RNA polymerase Plus (Ambion),
transcription buffer (Ambion), 16 mM MgCl2, 10 mM dithio-
threitol (DTT), 4 mM each of ATP, CTP, GTP and UTP and 40
units of RNasin (Promega). Reactions were incubated at 37uC for
1–2 hr and then RQ DNAse (Promega) was added and incubated
for an additional 15 min. RNA was phenol:chloroform extracted,
ethanol precipitated and resuspended in water. RNA was
quantified by measuring absorbance at 260 nm.
Radioactively-labeled intron transcripts were synthesized in
50 ml reactions containing 1 mg of PCR generated template,
0.5 mM each of ATP and GTP, 0.1 mM UTP and CTP, 2.5 mlo f
[
32P]-UTP and [
32P]-CTP (ICN) and 2 ml of 200 U/ml T7 RNA
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1 hr and then digested with DNase I for 15 min at 37uC.
Transcripts were purified on 10% denaturing polyacrylamide gels
and then processed as described for the splicing substrates.
Identification of fosB splicing products
Products of splicing reactions using transcripts generated from the
fosB minigene constructs were cut out of the gel and eluted
overnight in Elution Buffer. RNA was ethanol precipitated and
reverse transcribed into cDNA (SuperScript II RT, Stratagene) in
a2 0ml reaction containing 50 ng random primers, 5 ml of RNA
and 1 ml dNTP mix (10 mM each). The mixture was heated to
65uC for 5 min and 4 mlo f5 6first strand buffer, 2 ml of 0.1 M
DTT and 1 ml RNaseOUT (40 units/ml) were added to the
reaction. SuperScript II RT (1 ml, 200 U/ml, Invitrogen, Carls-
bad, CA) was added to the reaction and incubated at 42uC for
50 minutes. The reaction was inactivated by incubation for
15 min at 70uC. PCR reactions (50 ml) contained 5 ml1 0 6PCR
buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 1.5 ml5 0m M
MgCl2, 10 mM dNTP mix, 1 ml forward primer (10 mM), 1 ml
reverse primer (10 mM), 0.4 ml Taq DNA polymerase (5U/ml) and
2 ml cDNA. When intron 4 spliced (IS) and intron 4 retained (IR)
RNAs were amplified, a set of E4- and E5-specific primers were
used (Table 1). An I4-specific forward primer and an E5-specific
reverse primer were used to amplify lariat structures (Table 1).
Samples underwent 35 cycles of amplification using the following
cycling parameters: 15 sec at 94uC, 15 sec at 60uCo r6 6 uC
depending on the primers used, and 30 sec at 68uC. The PCR
products were separated on 2% agarose gels.
UV cross-linking assays
UV cross-linking assays were done as previously described [51].
Assays contained 50,000 cpm of [
32P]UTP labeled 59, middle and
39 substrates in a 10 ml reaction containing 5 ml of HeLa extract
(2.6 mg/ml). UV cross-linking reactions were assembled on ice,
incubated for 3 min at 30uC and then irradiated in open 1.5 ml
centrifuge tubes with 1.2 J, 6.5 cm from a UV light source using
a Stratalinker (Stratagene). After exposure to UV light, the
reactions were incubated with RNase A (1 mg/ml, Sigma-Aldrich,
Saint Louis, MO) for 20 min at 30uC. Reactions were terminated
by the addition of protein loading buffer and heating at 95uC for
5 min before loading on 10% SDS polyacrylamide gels. The gels
were fixed with 45% methanol and 9% acetic acid before drying
and exposing to film.
UV cross-linking immunoprecipitations
Uniformly-labeled [
32P]UTP 59, middle or 39 RNA substrates were
UV cross-linked and RNase A treated as described above. A 10 ml
aliquot of a 1:50 dilution of the anti-PTB antibody, Bb7 [52] (a gift
of Dr. D.L. Black, UCLA), anti-U2AF
65 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) or nonspecific antibody (anti-RIF 2C1, a gift
of Dr. K. Beaman, RFUMS) was added to each reaction and
incubated at 4uC overnight. The following day 20 ml of Protein A
agarose (Roche Diagnostics, Mannheim, Germany) was added to
each reaction prior to incubation at room temperature for 1 hr.
NET buffer (1 ml) containing 50 mM TrisHCl pH 7.5, 150 mM
NaCl, 5 mM EDTA and 0.5% NP40 was added to each sample.
Precipitates were collected by centrifugation at 6006ga t4 uC for
30 sec. The samples were washed four times in NET buffer. After
the final wash the precipitate was resuspended in loading buffer,
boiled for 3 min and then loaded on 10% SDS polyacrylamide
gels. The gels were fixed with 45% methanol and 9% acetic acid
before drying and exposing to film.
Cell Culture and Transient expression assays
HeLa cells were cultured in DMEM supplemented with 10% fetal
bovine serum. His-tagged PTB 1 (human PTB 1, a gift from Dr. J.
Patton, Vanderbilt University), was transiently transfected into
HeLa cells plated at ,75% confluency in a 100 mm culture dish
using the Lipofectamine reagent (Invitrogen) according to the
manufacturer’s protocol. Twenty four hours after transfection the
cells were trypsinized and replated into two 100 mm culture dishes
and cell lysates were collected the following day for protein
isolation as described below. Slight modifications of the methods
described above were also used to transiently transfect pBS
(bluescript); ISS/WT; ISS/T6; and PTB 1 constructs into HeLa
cells for RNA analysis. Cells were plated into 12 well culture plates
(,35% confluency) ,4 hr prior to transfection. Each experimen-
tal condition was performed in duplicate. Additionally, each
experimental protocol was performed at least three times. Forty-
eight hr post-transfection RNA was isolated using the Trizol
method, DNase-treated as described above, and cDNA generated.
The cDNA was amplified by PCR using a forward primer designed
to be complementary to sequencewithin the pGL3 vector, therefore,
only ectopically expressed fosB sequence was amplified. The reverse
primer was located in exon 5, thus allowing the amplification of both
fosBandDfosBcDNAina PCR reaction with a singleset of primers.
Control PCR reactions with primers specific for GAPDH were also
performed. The amplified products were resolved on 2.5% agarose
gels then imaged and quantitated using Kodak 1D Image Analysis
Software (Kodak, Rochester, NY).
PTB protein isolation
The Ni-NTA Purification System (Invitrogen) was used for the
purification of polyhistidine-containing recombinant proteins.
Cells were suspended in 1.5 ml native binding buffer (250 mM
NaH2PO4 pH 8.0/2.5 M NaCl) supplemented with a protease
inhibitor cocktail (Roche Diagnostics) and a phosphatase inhibitor
cocktail (1:100, Sigma-Aldrich). Cells were lysed by a freeze-thaw
cycle and the DNA sheared by passing the resulting cell lysate
through an 18-gauge needle followed by centrifuged at 3,0006gf o r
15 min. Ni-NTA columns were prepared by washing 75 mlo fN i -
NTA agarose three times with native binding buffer. Lysate (1.5 ml)
was then incubated on the column for 30 min, followed by four
washes with native wash buffer (native binding buffer supplemented
with 20 mM imidazole, pH 8.0). The supernatant was discarded
and protein was eluted with 150 ml native elution buffer (native
binding buffer supplemented with 250 mM imidazole, pH 8.0).
Extracts were loaded into Slide-A-Lyzer Mini Dialysis Units (10,000
MWCO, Pierce, Rockford, IL) and dialyzed overnight into Buffer D
(20 mM HEPES-KOH pH 8.0, 20% glycerol, 100 mM KCl and
0.2 mM EDTA pH 7.9). Purified proteins were examined by
Western blotting using PTB or His-tag specific antibodies.
Phosphatase treatment and PKA assay
Uniformly-labeled [
32P]UTP and [
32P]CTP fosB RNA substrates
containing the 39 end of I4 were UV cross-linked and RNase A
treated as described above. Six microliters of purified His-tagged
PTB (0.25 mg/ml) was used in the cross-linking assays. For
phosphatase treatment, protein was pre-incubated for 15 min
with NE Buffer 3 (50 mM Tris-HCl pH 7.9, 100 mM NaCl,
10 mM MgCl2 and 1 mM DTT) followed by a 50 min incubation
at 37uC with 3 ml (10 U/ml) of calf intestinal alkaline phosphatase
(CIP, New England Biolabs, Ipswitch, MA). For the PKA
phosphorylation reaction, protein was incubated with 3 ml of the
catalytic subunit of cAMP dependent protein kinase (New England
Biolabs, 2,500 U/ml), 200 mM ATP, 16 PKA Reaction Buffer
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volume of 30 ml, for 1 hr at 30uC. Some of the His-tagged protein
samples were phosphatase and PKA treated. In these instances,
the phosphatase step was performed while the protein was still on
the nickel beads, followed by wash out of the phosphatase, elution
of the His-tagged protein and subsequent PKA treatment.
Western blot analysis
Samples were mixed with an equal volume of 26 SDS sample
buffer (125 mM TrisHCl pH 6.8, 20% glycerol, 4% SDS, 0.2% 2-
mercaptoethanol (2-ME) and 0.001% bromphenol blue), boiled
for 3 min and resolved by electrophoresis in an 8% SDS-
polyacrylamide gel. Proteins were transferred to PVDF-Plus
transfer membranes (Fisher Scientific, Pittsburgh, PA) for
immunoblotting, using a semi-dry transfer apparatus (Owl
Scientific, Woburn, MA) according to manufacturer’s instructions.
PVDF membranes were then rinsed three times in 0.1%
Tween-20 in TBS (TBS-T), blocked with 2% milk for 1 hr at room
temperature, incubated with either PTB antibody (1/4,000
dilution; a gift of Dr. D.L. Black, UCLA) overnight at 4uC,
washed with TBS-T and incubated for 60 min at room
temperature with ECL peroxidase-labelled anti-mouse IgG (1/
4,000; Amersham Biosciences). After three final washes in TBS-T,
membranes were rinsed in TBS, immersed in chemiluminescence
detection reagent (ECL Plus, Amersham Biosciences) and exposed
to HyperFilm ECL film (Amersham Biosciences). Antibodies were
stripped from the membrane by incubating in 62.5 mM TrisHCl
(pH 6.8), 2% SDS, 100 mM 2-ME at 50uC for 30 min. Blots were
then probed with an a-polyhistidine antibody (1/3,000 dilution;
Clone His 1, Sigma-Aldrich). Images were captured using Kodak
1D Image Analysis Software.
PTB depletion
Transcripts which have been shown to effectively deplete PTB
from HeLa nuclear extracts [53] were generated from a plasmid
containing the CUCUU-octamer sequence (a gift of Dr. C.W.
Smith, University of Cambridge). RNA transcription was carried
out in the presence of 100 mM biotin-14-CTP as previously
described [53]. The biotinylated RNA was then bound to
streptavidin magnetic beads (Invitrogen; 100 pmol of RNA/
50 ml of beads) in 26BW buffer (10 mM TrisHCl pH 7.5, 1 mM
EDTA, 2 M NaCl). One hundred microliters of HeLa nuclear
extract (2.6 mg/ml) was preincubated with 0.5 ml of 100 mM DTT
and 34 U of RNasin for 15 min at room temperature, followed by
incubation with the RNA-streptavidin beads for 30 min, using
1,440 fmol of RNA/ml of extract. The beads were removed from
the extract using a magnet as described by the manufacturer.
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